Literature DB >> 938610

In vitro production of a transfer factor specific for transitional-cell carcinoma of the bladder.

G Pizza, D Viza, C Boucheix, F Corrado.   

Abstract

Human dialysable Transfer Factor (TFd) extracted from lymphocytes of patients with transitional cell carcinoma of bladder (TCCB) was replicated in culture by lymphoblastoid cell lines. The effectiveness of two such TFdLs produced in vitro in transferring sensitivity to TCCB was assessed in the lymphocyte migration test (LMT) using formalin-treated TCCB cells as antigen. The results, showed that one TFdL transferred sensitivity in 5/14 cases and the other in 12/15, not only to leucocytes of healthy individuals but also to leucocytes of TCCB patients. Preliminary results showing an in vivo transfer of sensitivity are discussed.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 938610      PMCID: PMC2025116          DOI: 10.1038/bjc.1976.98

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  6 in total

1.  In vitro study of cellular immunity against autochthonous human cancer.

Authors:  A Segall; O Weiler; J Genin; J Lacour; F Lacour
Journal:  Int J Cancer       Date:  1972-03-15       Impact factor: 7.396

2.  Lymphocyte cytotoxicity in bladder cancer. No requirement for thymus-derived effector cells?

Authors:  C O'Toole; P Perlmann; H Wigzell; B Unsgaard; C G Zetterlund
Journal:  Lancet       Date:  1973-05-19       Impact factor: 79.321

3.  Letter: Formalin-fixed tumour cells in the leukocyte migration test.

Authors:  C E Ross; A J Cochran; D E Hoyle; R M Grant; R M Mackie
Journal:  Lancet       Date:  1973-11-10       Impact factor: 79.321

4.  Cell-mediated cytotoxicity against human bladder cancer.

Authors:  E T Bloom; R C Ossorio; S A Brosman
Journal:  Int J Cancer       Date:  1974-09-15       Impact factor: 7.396

5.  Immune response to urinary bladder tumours in man.

Authors:  J Bubeník; P Perlmann; K Helmstein; G Moberger
Journal:  Int J Cancer       Date:  1970-01-15       Impact factor: 7.396

6.  Osteogenic sarcoma. Immunologic parameters before and during immunotherapy with tumor-specific transfer factor.

Authors:  A S Levin; V S Byers; H H Fudenberg; J Wybran; A J Hackett; J O Johnston; L E Spitler
Journal:  J Clin Invest       Date:  1975-03       Impact factor: 14.808

  6 in total
  2 in total

1.  Transfer factor: a potential agent for immunotherapy of cancer.

Authors:  C R Meier; A F LoBuglio
Journal:  World J Surg       Date:  1977-09       Impact factor: 3.352

2.  Inhibition or augmentation of PHA-induced lymphocyte transformation by factors of calculated lymphoblastoid cell lines.

Authors:  M Pinto; A Mizrahi
Journal:  Experientia       Date:  1979-04-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.